source
- Apnimed secures $192 million IPO to fund sleep-apnea drug program targeting 2027 launchApnimed, a biotech focused on sleep apnea, announced it raised $192 million through an initial public offering. The capital will be used to advance its lead drug candidate, with plans to begin a l…
- American Regent recalls two lots of Adequan canine injection and two lots of Adequan i.m. for horses due to glass fibersAmerican Regent Animal Health announced a nationwide recall of specific lots of its Adequan products for dogs and horses. The recall includes two lots of the 100 mg/mL 5 mL multi‑dose canine injec…